Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial idarubicin + Lipiodol for hepatocellular carcinoma with Child-Pugh A/B7 cirrhosis
2024-515456-20-00Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idarubicin and ethiodized oil in hepatocellular carcinoma (HCC), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Disease control rate at 4 months. Started Aug 2024; status: completed.
02
Drugs
idarubicinethiodized oil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-515456-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515456-20-00.